Kiromic BioPharma Reports Promising Interim Results in Phase 1 Deltacel-01 Trial for Advanced NSCLC Patients
Houston-based biotech firm Kiromic BioPharma, Inc. (OTCQB: KRBP) has released interim results that are near the completion of Part 1 of its Deltacel-01 Phase 1 clinical trial. This trial is a critical step in evaluating the efficacy and safety of Deltacel (KB-GDT-01), Kiromic’s innovative allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy. Targeted at patients suffering from stage 4 metastatic non-small cell lung cancer (NSCLC) who have not responded to standard treatments, the trial is generating much anticipation within the medical community.
About the Trial
The Deltacel-01 Phase 1 trial is designed to assess Deltacel as a new form of immunotherapy for patients who are grappling with the devastating effects of advanced NSCLC. Unlike traditional treatments, Deltacel therapy utilizes allogeneic Gamma Delta T-cells, which are sourced from healthy donors. These cells are re-engineered to target and kill cancer cells, offering a potential groundbreaking solution for patients who have not seen success with established therapies.
Interim Results and Patient Data
The press release detailed the interim results from Part 1 of the Deltacel-01 trial, presenting data derived from five patients who have been evaluated for progression-free survival (PFS). Although complete results are yet to be released, the interim findings offer a promising outlook.
Key Points from the Interim Data
- ’Efficacy:’ Preliminary data have shown encouraging outcomes in terms of progression-free survival among the five evaluated patients, indicating that Deltacel may have a tangible effect on slowing the progression of stage 4 NSCLC.
- ’Safety:’ The interim results underline a favorable safety profile, with no significant adverse effects reported among the initial cohort of patients. This is a positive indicator for the potential scalability of Deltacel therapy.
- ’Quality of Life:’ Early results also suggest improvements in the quality of life of the patients involved, signaling the possibility that Deltacel can offer not just life-extension but also life-enhancing benefits.
Kiromic BioPharma highlighted that more comprehensive data would be available upon the full completion of Part 1 of the study.
Future Prospects
The interim results offer a glimmer of hope for a patient population that often faces bleak outcomes. According to the American Cancer Society, the 5-year survival rate for stage 4 NSCLC is approximately 7%, underscoring the urgent need for innovative treatments like Deltacel.
Dr. Maurizio Chiriva-Internati, CEO of Kiromic BioPharma, expressed optimism about the initial results, stating, “We are encouraged by the interim findings from Part 1 of the Deltacel-01 trial. These early signs of efficacy and safety strengthen our resolve to advance this promising therapy through the clinical trial process, bringing it one step closer to patients in need.”
Conclusion
Kiromic BioPharma’s interim results from the Deltacel-01 Phase 1 clinical trial underline the potential of Deltacel as an effective treatment for patients with stage 4 metastatic NSCLC who have exhausted traditional therapy options. The favorable preliminary data on both progression-free survival and safety profile sets the stage for further validation in the upcoming parts of the trial.
As Kiromic BioPharma continues to advance its clinical research, the medical community remains hopeful that Deltacel could revolutionize the treatment landscape for advanced NSCLC, ultimately improving patient outcomes and saving lives.
Comments